Literature DB >> 28501971

Electrolyte and Acid-Base Disturbances in End-Stage Liver Disease: A Physiopathological Approach.

José Víctor Jiménez1, Diego Luis Carrillo-Pérez2, Rodrigo Rosado-Canto2, Ignacio García-Juárez3, Aldo Torre3, David Kershenobich3, Eduardo Carrillo-Maravilla4.   

Abstract

Electrolyte and acid-base disturbances are frequent in patients with end-stage liver disease; the underlying physiopathological mechanisms are often complex and represent a diagnostic and therapeutic challenge to the physician. Usually, these disorders do not develop in compensated cirrhotic patients, but with the onset of the classic complications of cirrhosis such as ascites, renal failure, spontaneous bacterial peritonitis and variceal bleeding, multiple electrolyte, and acid-base disturbances emerge. Hyponatremia parallels ascites formation and is a well-known trigger of hepatic encephalopathy; its management in this particular population poses a risky challenge due to the high susceptibility of cirrhotic patients to osmotic demyelination. Hypokalemia is common in the setting of cirrhosis: multiple potassium wasting mechanisms both inherent to the disease and resulting from its management make these patients particularly susceptible to potassium depletion even in the setting of normokalemia. Acid-base disturbances range from classical respiratory alkalosis to high anion gap metabolic acidosis, almost comprising the full acid-base spectrum. Because most electrolyte and acid-base disturbances are managed in terms of their underlying trigger factors, a systematic physiopathological approach to their diagnosis and treatment is required.

Entities:  

Keywords:  Acid–base imbalance; End-stage liver disease; Hypokalemia; Hyponatremia; Liver transplantation

Mesh:

Year:  2017        PMID: 28501971     DOI: 10.1007/s10620-017-4597-8

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  156 in total

Review 1.  EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.

Authors: 
Journal:  J Hepatol       Date:  2010-06-01       Impact factor: 25.083

2.  Predicting mortality in cirrhosis--serum sodium helps.

Authors:  Andrés Cárdenas; Pere Ginès
Journal:  N Engl J Med       Date:  2008-09-04       Impact factor: 91.245

Review 3.  Urine electrolytes and osmolality: when and how to use them.

Authors:  K S Kamel; J H Ethier; R M Richardson; R A Bear; M L Halperin
Journal:  Am J Nephrol       Date:  1990       Impact factor: 3.754

Review 4.  Disorders of plasma sodium--causes, consequences, and correction.

Authors:  Richard H Sterns
Journal:  N Engl J Med       Date:  2015-01-01       Impact factor: 91.245

5.  Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial.

Authors:  Alexander L Gerbes; Veit Gülberg; Pere Ginès; Guy Decaux; Peter Gross; Hassan Gandjini; Jacques Djian
Journal:  Gastroenterology       Date:  2003-04       Impact factor: 22.682

6.  The effect of hyponatremia on the outcome of patients after orthotopic liver transplantation.

Authors:  A Karapanagiotou; C Kydona; S Papadopoulos; C Dimitriadis; T Giasnetsova; G Rempelakos; M Passakiotou; I Fouzas; V Papanikolaou; N Gritsi-Gerogianni
Journal:  Transplant Proc       Date:  2012-11       Impact factor: 1.066

7.  Prognostic significance of hypokalemia in hepatic encephalopathy.

Authors:  Vinaya Gaduputi; Chaitanya Chandrala; Naeem Abbas; Hassan Tariq; Sridhar Chilimuri; Bhavna Balar
Journal:  Hepatogastroenterology       Date:  2014 Jul-Aug

8.  Influence of high donor serum sodium levels on early postoperative graft function in human liver transplantation: effect of correction of donor hypernatremia.

Authors:  E Totsuka; F Dodson; A Urakami; N Moras; T Ishii; M C Lee; J Gutierrez; M Gerardo; E Molmenti; J J Fung
Journal:  Liver Transpl Surg       Date:  1999-09

9.  Increased immunoglobulin A in alcoholic liver cirrhosis: exploring the response of B cells to Toll-like receptor 9 activation.

Authors:  B Massonnet; A Delwail; J-M Ayrault; C Chagneau-Derrode; J-C Lecron; C Silvain
Journal:  Clin Exp Immunol       Date:  2009-10       Impact factor: 4.330

10.  Implications of Hyponatremia in Liver Transplantation.

Authors:  Sertac Cimen; Sanem Guler; Subhashini Ayloo; Michele Molinari
Journal:  J Clin Med       Date:  2014-12-29       Impact factor: 4.241

View more
  8 in total

Review 1.  Approach to Hyponatremia in Cirrhosis.

Authors:  Bashar Attar
Journal:  Clin Liver Dis (Hoboken)       Date:  2019-04-30

2.  Practical Issues in the Management of Overt Hepatic Encephalopathy.

Authors:  Ganesh Pantham; Kevin D Mullen
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-11

Review 3.  A narrative review of nutritional abnormalities, complications, and optimization in the cirrhotic patient.

Authors:  Edgewood R Warner; Fuad Z Aloor; Sanjaya K Satapathy
Journal:  Transl Gastroenterol Hepatol       Date:  2022-01-25

Review 4.  Clinical Implications, Evaluation, and Management of Hyponatremia in Cirrhosis.

Authors:  Dibya L Praharaj; Anil C Anand
Journal:  J Clin Exp Hepatol       Date:  2021-09-16

5.  Serum potassium levels and prognosis in HBV-associated decompensated cirrhosis.

Authors:  JianJiang Huang; Ming Cai; Xia He
Journal:  J Clin Lab Anal       Date:  2021-05-05       Impact factor: 2.352

6.  Admission Serum Bicarbonate Predicts Adverse Clinical Outcomes in Hospitalized Cirrhotic Patients.

Authors:  Michael Schopis; Anand Kumar; Michael Parides; Adam Tepler; Samuel Sigal
Journal:  Can J Gastroenterol Hepatol       Date:  2021-05-17

7.  Association between serum albumin and cognitive dysfunction in hepatic encephalopathy: An exploratory data analysis.

Authors:  Kosuke Kaji; Kiwamu Okita; Kazuyuki Suzuki; Ikuya Sato; Masaki Fujisawa; Hitoshi Yoshiji
Journal:  JGH Open       Date:  2020-12-07

Review 8.  Dysregulation of Astrocytic Glutamine Transport in Acute Hyperammonemic Brain Edema.

Authors:  Magdalena Zielińska; Jan Albrecht; Mariusz Popek
Journal:  Front Neurosci       Date:  2022-06-06       Impact factor: 5.152

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.